Rate My Professor Ahmad Shariftabrizi

Dr. Shariftabrizi earned his MD from Tehran University of Medical Sciences in Iran. He completed a residency in Nuclear Medicine and Molecular Imaging at the State University of New York at Buffalo, followed by fellowships in PET/CT at the University of Pittsburgh Medical Center and Nuclear Oncology at Memorial Sloan Kettering Cancer Center. He is board certified by the American Board of Nuclear Medicine and the Certification Board of Nuclear Cardiology, and holds the SNMMI Certificate of Qualification to Perform, Supervise, and Interpret PET/CT. His professional memberships include the American College of Radiology, Society of Nuclear Medicine & Molecular Imaging, American College of Nuclear Medicine, American Association for Cancer Research, American College of Physicians, and American Physician Scientists Association. In research, he focuses on molecular imaging and therapy, serving as faculty in the Department of Radiology PET Center and participating in the Iowa Neuroendocrine Tumor SPORE as Interim Division Chief of Nuclear Medicine at the VA Medical Center. He has guest edited special issues on PET/CT Imaging in Oncology: Clinical Updates and Future Directions, PET/CT in Cancers Outcomes Prediction, and Radioligand Therapy in Cancer. Notable publications include 'Optimization of Radium-223 Treatment of Castration-resistant Prostate Cancer with PSMA PET/CT' (The Oncologist, 2023), 'Inter- and intra-tumoral heterogeneity on [68Ga]Ga-DOTATATE PET/CT in neuroendocrine tumors' (European Journal of Hybrid Imaging, 2024), 'Renal graft imaging: An update and overview' (Seminars in Nuclear Medicine, 2026), 'Hepatic Vascular Shunts Mimicking Malignant Lesions on 18F-FDG PET/CT Imaging' (Cureus, 2026), and 'Visualization of Enteric Duplication Cyst on Meckel's Scan' (Clinical Case Reports, 2025). He sponsors the clinical trial NCT06586047 on Breast Cancer PSMA PET imaging.